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Summary objective To assess the efﬁcacy of chloroquine in the treatment of Plasmodium vivax malaria in in
Dawei District, southern Myanmar.
methods Enrolled patients at Sonsinphya clinic >6 months of age were assessed clinically and para-
sitologically every week for 28 days. To differentiate new infections from recrudescence, we genotyped
pre- and post-treatment parasitaemia. Blood chloroquine was measured to conﬁrm resistant strains.
results Between December 2002 and April 2003, 2661 patients were screened, of whom 252 were
included and 235 analysed. Thirty-four per cent (95% CI: 28.1–40.6) of patients had recurrent para-
sitaemia and were considered treatment failures. 59.4% of these recurrences were with a different
parasite strain. Two (0.8%) patients with recurrences on day 14 had chloroquine concentrations above
the threshold of 100 ng⁄ml and were considered infected with chloroquine resistant parasites. 21% of
failures occurred during the ﬁrst 3 weeks of follow-up: early recurrence and median levels of blood
chloroquine comparable to those of controls suggested P. vivax resistance.
conclusions Plasmodium vivax resistance to chloroquine seems to be emerging in Dawei, near the
Thai-Burmese border. While chloroquine remains the ﬁrst-line drug for P. vivax infections in this area of
Myanmar, regular monitoring is needed to detect further development of parasite resistance.
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Introduction
Plasmodium vivax is an important cause of human malaria
and is commonly found in most of Asia, and in parts of the
Americas, Europe and North Africa (WHO and UNICEF
2005). Although rarely lethal, P. vivax malaria is respon-
sible for an important morbidity, mainly in children and in
pregnant women; the infection has been associated with
low birth weight (Nosten et al. 1999). Chloroquine is the
drug of choice for P. vivax malaria, although in recent
years resistance to this drug has been demonstrated in
several countries. Resistance of P. vivax to chloroquine
was ﬁrst reported from Papua New Guinea in 1989
(Rieckmann et al. 1989) 1 and subsequently in Indonesia
(Baird et al. 1997b; Fryauff et al. 1998b) and India (Dua
et al. 1996; Singh 2000). In Myanmar, the ﬁrst cases of
P. vivax resistant to chloroquine were reported in 1993
(Myat-Phone-Kyaw et al. 1993) 4 and two years later a study
showed that chloroquine was losing its efﬁcacy against
P. vivax (Marlar-Than et al. 1995).
In Dawei District (south of Myanmar) where Me ´decins
sans Frontie `res (MSF) works in collaboration with the
Ministry of Health (MoH), half of the patients consulting
for fever are conﬁrmed as malaria cases, of whom almost
half are due to P. vivax (MoH and MSF, unpublished
data). In 2002–2003, there was no data on P. vivax
sensitivity to chloroquine in this area, except one study
conducted a few years before on the other side of the Thai-
Myanmar border showing that chloroquine remained
highly effective (Luxemburger et al. 1999). In Dawei,
however, there was a belief among clinicians that a
proportion of P. vivax cases were failing to chloroquine.
Observations were made of patients returning to the clinic
2–3 weeks or later after drug administration. These para-
sites reappearing after treatment could be re-infections,
relapses from the liver (as patients do not receive
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survived therapy (resistant parasites) (Baird 2004). The fact
that they occurred before day 28 suggested recrudescence
of the admission isolates (Baird et al. 1997). Our aim
was to better document the therapeutic response of
P. vivax to chloroquine and therefore to assess whether the
drug was still sufﬁciently effective.
Materials and methods
Study site
The study was conducted in Dawei District (460 000
inhabitants), a rural area located in the south of the
country near the Thai-Myanmar border. Patients were
recruited at Sonsinphya clinic, supported by MSF and
located in a rural area 2 h by car from the district capital
Dawei. The clinic, which covers a large population (mainly
rice farmers) living in the surrounding area, is composed of
a consultation ward, a small inpatient unit and a labora-
tory fully equipped for malaria microscopic diagnosis,
which is done by trained personnel. Malaria represents the
most important reason for consultation. Malaria is peren-
nial; however most of the cases are seen during the rainy
season, which peaks from June to August. The vast
majority of cases (>80%) are over 5 years old. Plasmodium
vivax cases (40% of the total malaria infections) are
treated with chloroquine. Primaquine, although indicated
in the National Protocol, is not administered because of the
10–15% prevalence of G6PD deﬁciency and the high risk
of haemolytic disorders (Matsuoka et al. 2004).
Design
This study was based on the WHO guidelines (WHO 2001,
2002 5 . Patients of all ages above 6 months suffering from
uncomplicated P. vivax malaria monoinfection were
enrolled, treated on site with chloroquine and followed-up
for 28 days. Parasitological examination was performed
weekly and patients’ symptoms were recorded at each visit.
Genotyping by PCR and measurement of blood chloro-
quine concentrations in all recurrent infections and in a
sample of controls assisted in the interpretation of results.
With a level of signiﬁcance of 95%, an estimated failure
rate of 5% with a 5% precision, and a dropout rate of
10%, 80 individuals were required. This was multiplied by
three to allow a stratiﬁed analysis by age group (under
5⁄5–14⁄15+), yielding a ﬁnal sample of 240 individuals.
Patients presenting at the consultation with clinical
malaria and a positive slide for P. vivax were eligible. They
were referred to the study clinic and included if they (i)
were aged 6 months or older, (ii) had fever (axillary
temperature ‡37.5  C) or a history of fever in the past
48 h, (iii) had a P. vivax mono-infection with an asexual
count above 250⁄ll, and (iv) were likely to complete
28 days of follow-up (easy access to the study clinic
according to a pre-deﬁned list of villages). Exclusion
criteria were (i) severe malnutrition, (ii) concomitant
febrile illnesses, (iii) chronic infectious disease (i.e. tuber-
culosis), (iv) history of allergy to chloroquine, and (v)
pregnancy. Written informed consent was obtained from
each patient or parents⁄guardians. The study was
approved by the Ethical Committee of the Ministry of
Health, Myanmar.
Treatment and follow-up
Patients were treated with oral chloroquine (Nivaquine
 ,
Rhone Poulenc Rorer, Ireland, tablets containing 150 mg
chloroquine base) using the WHO standard schedule:
10 mg base⁄kg (ﬁrst and second days), and 5 mg base⁄kg
(third day). For children, tablets were crushed and mixed
with syrup on a spoon. Drug administration was super-
vised and patients remained at the study clinic for 1 h
afterwards. In case of vomiting within 30 min, the full dose
was given again; if vomiting occurred between 30 and
60 min after administration, another half-dose was given.
After the treatment period (days 0, 1, 2) patients were
reassessed on days (D) 3, 7, 14, 21 and 28. At each visit, a
clinical examination was made, and thick and thin smears
were obtained. In case of recurrent P. vivax parasitaemia, a
second capillary blood sample was collected for PCR
genotyping and chloroquine measurements. For each
recurrent parasitaemia, a patient at the same day of follow-
up with no recurrence (considered as a control) was also
sampled for chloroquine measurement. Defaulters were
visited at home, and classiﬁed as lost to follow-up if they
did not attend the 28th day consultation. Patients were
secondarily excluded in case of: (i) failure to take any
dose of chloroquine, (ii) allergic reaction to chloroquine
severe enough to prescribe the alternative treatment (e.g.
pruritus or rash), (iii) detection of a mixed malaria
infection during follow-up, (iv) vomiting two times after
drug administration, and (v) withdrawal of consent.
Endpoints
Patients were classiﬁed as ‘treatment success’ in the absence
of parasite reappearance within 28 days of follow-up. They
were classiﬁed as ‘treatment failure’ in case of reappear-
ance of parasites during follow-up. As no molecular
method allows a clear differentiation of P. vivax recur-
rences (Baird 2004), failures were considered as relapses or
re-infections (in case of different genotype) or relapses or
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(whatever the genotype, i.e. same or different) occurred in
the presence of blood chloroquine concentrations (chloro-
quine + desethylchloroquine (DCQ)) above 100 ng⁄ml,
they were considered resistant (Baird 2004). Lower con-
centrations were inconclusive, however early recurrence
(within the ﬁrst 3 weeks of follow-up) was considered
suggestive of parasite resistance (Baird 2004). All recurrent
parasitaemias received a 7D course of artesunate.
Laboratory procedures
Thick and thin smears were stained with Giemsa 10% (pH
7.2) for 20 min. Determination of the Plasmodium species
was done on a thin smear. Plasmodium vivax asexual
counts were obtained on the thick smear by counting the
number of trophozoites against 200 leucocytes (WBC) or
500 leucocytes if the number of asexual parasites was
below 10 per 200 WBC, assuming a normal blood level of
8000 WBC⁄ll. A ﬁlm was reported negative only after
examining at least 200 ﬁelds. A trained technician was
responsible for an internal quality control implying a
second and a third reading of the slides in case of
discrepancy between ﬁrst and second readings. Eight
hundred and thirty-six slides (55% of the total) were
sampled and re-read by an independent technician at the
Shoklo Malaria Research Unit (Thailand), showing a
sensitivity of 99% (three false positive out of 346 positive
slides) and a speciﬁcity of 98% (11 false negative out of
482 negative slides). Samples for genomic analysis and
chloroquine measurements were collected separately on
Whatmann N 3 ﬁlter paper, air-dried, and stored in the
dark in sealed bags at room temperature.
Genetic characterization of P. vivax was performed at
Department of Clinical Tropical Medicine, Faculty of
Tropical Medicine, Mahidol University. Parasite DNA was
extracted from blood spot using Qiagen Kit (Santa Clarita,
CA, USA). Three parasite loci, circumsporozoite protein
(CS), Merozoite surface protein 1 and 3 (MSP1 and MSP3)
which exhibit repeated number of polymorphisms, were
studied by using a PCR-RFLP method (Bruce et al. 1999;
Imwong et al. 2005). The PCR products were detected by
electrophoresis of 10 ll from each reaction on 1.5%
Agarose gels, visualized by staining with ethidium bromide
and UV ﬂorescence, and size against a 100 bp molecular
weight marker (Gibco-BRL Life Technologies).
Chloroquine and desethylchloroquine (DCQ) concen-
trations were determined at the Pharmacology Laboratory,
Wellcome Unit, Mahidol University, Bangkok using solid
phase extraction (SPE) and liquid chromatography (LC)
(Lindega ˚rdh et al. 2002). The blood spots were extracted
for approximately 1 h using 2.0 ml perchloric acid
(0.3 M), 1.0 ml acetonitrile and 5.0 ml phosphate buffer
(pH 2; 0.05 M) containing internal standard. The liquid
phase was thereafter loaded onto IST PRS (Argonaut) SPE
columns. The SPE eluates were evaporated, reconstituted
and injected into the LC-system (SB-CN column; Zorbax
Inc.) using a mobile phase containing 0.01 m sodium
perchlorate and acetonitrile-phosphate buffer (pH 2;
0.1 M) (16:84, v⁄v). Duplicates of quality control samples
at three different concentrations were analysed with each
set of unknown samples. The total variations for chloro-
quine were 3.5%, 3.1% and 4.3% at 64, 383 and
892 ng⁄ml, respectively. The total variations for DCQ
were 4.0%, 3.0% and 4.2% at 55, 329 and 769 ng⁄ml,
respectively.
Data entry and analysis
Data were entered on Microsoft Excel, individually
checked, and analysed on stata 8.2 (Stata Corporation,
College Station). Results were expressed as percentages
with associated 95% conﬁdence interval (CI) and com-
pared between age groups. Comparisons of categorical
variables were done by chi-squared or Fisher’s exact test
when appropriate. Non-parametric tests (Kruskal–Wallis
and Mann–Whitney) were used for the comparison of non-
normally distributed continuous variables.
Results
Study proﬁle and baseline characteristics of patients
Enrolment lasted from December 2002 to April 2003. In
total, 2661 persons were screened of whom 460 had
P. vivax mono-infections. Of these, 252 (55%) met all
inclusion criteria and were enrolled (Figure 1). Baseline
characteristics of included patients were similar in each age
group (Table 1). Three of 252 patients were lost to follow-
up (1.2%) and 14 (5.5%) were withdrawn (10 in the
‘under 5’ and 4 in the ‘15+’ age groups). Reasons of
withdrawal were vomiting (n = 6) and presence of a
P. falciparum infection during follow-up (n = 8). After
accounting for these losses, 73, 94 and 68 patients were
analysable at D28 in the ‘under 5’, 5–14’ and ‘15+’ groups,
respectively (Figure 1).
Parasitological responses
Out of the 235 patients analysed, 155 were classiﬁed as
treatment successes and 80 (34.0%, 95% CI 28.1–40.6) as
treatment failures, of whom only 1 had fever. The
proportion of failures was similar in the ‘<5’ and ‘5–14’ age
groups (49.3% vs. 39.4%, P = 0.20), whereas it was
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P < 0.001 for the comparisons both with the ‘<5’ and ‘5–
14’ age groups) (Table 2). Timing of recurrences was as
follows: 3 (3.7%) recurrences on D14, 16 (20%) on D21, 2
(2.5%) on D23, 1 (1.3%) on D25 and 58 (72.5%) on D28.
The median day of recurrence was D28 (range: 14–28) in
each of the three categories of age. Parasitaemia at
recurrence was usually low: 74⁄80 (92%) of recurrences
had parasite densities < 1000⁄ll, 56⁄80 (70%) < 500⁄ll
and 42⁄80 (52%) < 100⁄ll.
PCR analysis of Plasmodium strains
For 74 of the 80 treatment failures, a PCR result was
available (Figure 2). The majority of these recurrences
(44⁄74, 59.4%) occurred with a different strain. There
was no effect of age on the proportions of different
genotypes: 63.9% in the ‘<5’, 48.6% in the ‘5–14’ and
42.8% in the ‘15+’ age groups (P = 0.34). Proportions of
genotypes according to day of recurrence were as
follows: 66% (2⁄3) on D14, 40% (6⁄15) on D21, 0%
‘<5 years’
83
Analysed D28
73
Withdrawn
10
‘5–14 years’
95
Analysed D28
94
Lost to follow-up
1
’15 + years’
74
Analysed D28
68
Withdrawn
4
Lost to follow-up
2
Included
252
Screened
2661
2409 exclusions
Figure 1 Details of study inclusion and
follow-up, chloroquine efﬁcacy study,
Dawei, Myanmar 2002–2003.
Table 1 Baseline (day 0) characteristics of included patients, chloroquine efﬁcacy study, Dawei, Myanmar 2002–2003
Characteristic <5 years (n = 83) 5–14 (n = 95) 15+ (n = 74) P-value
Gender ratio (M⁄F) 1.02 1.21 0.61 0.08
Median axillary temperature ( C) (range) 37.0 (36.0–41.0) 36.8 (36.1–41.0) 36.8 (36.0–40.5) 0.39
Geometric mean asexual parasitaemia (⁄ll) (IQR) 3612 (1925–7210) 4155 (2713–7070) 3621 (1904–7234) 0.53
Per cent gametocyte carriage (95% CI) 97.6 (91.5–99.7) 94.7 (88.1–98.2) 95.9 (88.6–99.1) 0.17
IQR, interquartile range.
Table 2 Parasitological response by age group, chloroquine efﬁcacy study, Dawei, Myanmar, 2002–2003
Outcome
<5 years (n = 73) 5–14 (n = 94) 15+ (n = 68)
n % 95%CI n % 95%CI n % 95%CI
Treatment failure 36 49.3 37.6–61.1 37 39.4 29.3–49.2 7 10.3 2.9–17.7
Treatment success 37 50.7 38.7–62.6 57 60.6 50.0–70.5 61 89.7 79.9–95.7
Total 73 100 94 100 68 100
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Chloroquine measurements
A total of 137 samples were analysed for chloroquine and
DCQ whole blood concentrations, 79 were recurrences, 57
were controls and one sample was from a patient who was
secondarily excluded. The median chloroquine+DCQ
concentration was 39.9 ng⁄ml [interquartile range (IQR):
30.0–55.0] without any difference between recurrences
(median 39.9 ng⁄ml, IQR: 30.5–52.1) and controls (med-
ian 40.7 ng⁄ml, IQR: 30.8–52.1) (P = 0.90, Mann–Whit-
ney). At D21, median chloroquine+DCQ concentrations
were not statistically different between recurrences (med-
ian 43.9 ng⁄ml, IQR: 31.5–54.7) and controls (median
38.4 ng⁄ml, IQR: 35.3–70.2) (P = 0.66, Mann–Whitney).
This was also the case at D28 (median 33.7 ng⁄ml in
recurrences, median 34.4 ng⁄ml in controls, P = 0.57).
Two recurrences (both at D14) had chloroquine concen-
trations above the threshold of 100 ng⁄ml, demonstrating
resistance to chloroquine: the ﬁrst was caused by the same
strain (146.5 ng⁄ml, 8-year-old girl), the second by a
different strain (190.1 ng⁄ml, 8-month-old girl).
Summary results
Among the 80 failures, two had chloroquine blood
levels > 100 ng⁄ml (1 with a different genotype, one with
the same genotype) and were considered infected with
chloroquine resistant parasites. Among the remaining 78
failures with levels of chloroquine £ 100 (44 with a
different genotype, 33 with the same genotype, ﬁve with
genotyping not done), 17 occurred within 3 weeks of
follow-up which was very suggestive of resistance. Overall
19⁄235 (8%) patients treated with chloroquine were
considered as certainly or probably resistant (Figure 2).
Discussion
We investigated the efﬁcacy of chloroquine against P. vivax
in Dawei district, Myanmar. Our results suggest that
resistance is emerging in this area of South East Asia. These
conclusions are based on the following ﬁndings: presence
of two early recurrences on D14 with levels of chloro-
quine > 100 ng⁄ml; 34% recurrences during follow-up,
which is much higher than the 3% rate found several years
before in the neighbouring area of Mae Sot in Thailand
(Luxemburger et al. 1999); 23% recurrences occurring
Analysed 
235
Treatment success 
155
Treatment failures
80
>100 ng/ml ≤  ≤ 100 ng/ml Not done
genotype
Different
CQ + DCQ 
Same
genotype
Different Same Not done
genotype
Different Same Not done
Day failure
D14 1 1 1
D21 6 9 1
D23 2
D25 1
D28 36 17 4 1
Total 1 1 43 29 5 1
Figure 2 Summary results, chloroquine efﬁcacy study, Dawei, Myanmar 2002–2003.
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differs from the ﬁndings of Luxemburger et al. (1999), who
detected only one recurrence during this period.
One reason that could explain our high rate of recur-
rences is the lower chloroquine blood levels found in our
patients, compared to what has been described elsewhere.
Indeed, our mean⁄median levels of chloroquine were lower
than that found by other authors both at D28 (Taylor et al.
2000) and at recurrence (Fryauff et al. 1998; Sumawinata
et al. 2003). Low absorption or bioavailability could result
in a higher rate of recrudescences. However, in our study,
failures had similar chloroquine levels than successes
(controls), both overall and on day of recurrence. Hence,
low levels of chloroquine cannot explain recrudescing
patients. The difference in chloroquine levels with that
found in other studies could also possibly be explained by
differences in procedures used by different laboratories.
Overall, these data suggests that P. vivax resistance is
developing in Dawei area, as parasitaemia should not recur
within 35 days of standard chloroquine treatment (Baird
2004). They conﬁrm previous ﬁndings: a study published
15 years ago, where two cases of suspected P. vivax
resistance to chloroquine were reported (Myat-Phone-
Kyaw et al. 1993), and also later in vivo data showing
14% of recurrence by D14 (Marlar-Than et al. 1995).
They contradict, however, more recent in vivo (Vijaykadga
et al. 2004; Tasanor et al. 2006) and in vitro (Chotivanich
et al. 2004) data suggesting that there is no signiﬁcant
resistance of P. vivax to chloroquine in this area. As recent
in vivo data are scarce, further studies should be conducted
in order to better monitor and map resistance levels of
P. vivax to chloroquine in this speciﬁc area of South East
Asia.
Our results should be interpreted with caution because
they rely on the hypotheses raised (Baird et al. 1997a) in
a speciﬁc population from Irian Jaya. However, the
minimal effective concentration (MEC) of 100 ng⁄ml in
whole blood proposed by Baird has never been tested in
practice. This threshold is based on a ﬁxed blood⁄plasma
ratio of eight and a tested MEC in plasma of 12–
15 ng⁄ml (Berliner et al. 1948; Baird 2004). Blood⁄
plasma ratios of two to three can be seen in malaria cases
(Dua et al. 1999a,b). Chloroquine concentration and
chloroquine⁄chloroquine metabolite ratio in the blood
depend upon parasitaemia and chloroquine accumulates
differently to that of the chloroquine metabolites in
infected red blood cells (Ajayi et al. 1989). These issues
raised the question of whether the blood⁄plasma ratio
in the population investigated in our study was the
same to that observed by Baird, or closer to the lower
ratios reported by other authors. A study conducted in
2004 in 16 P. vivax infected patients living around the
Thai-Burmese border showed large inter-individual
differences in chloroquine blood⁄plasma ratios (chloro-
quine + DCQ) with the median being similar to the
ratio proposed by Baird: median 8.9 (range: 3.8–18.4)
(Niklas Lindegardh, personal communication). Further-
more the ratio tended to increase with time after drug
administration (median5h = 4.1, median168h = 6.7 and
median672h = 8.9) in malaria infected patients, which
could be explained by the malaria associated thrombo-
cytopenia. These ﬁndings raise the question whether
equivalent blood concentrations for recrudescing patients
and controls would necessarily mean that the plasma
concentrations also are equivalent in our study. If
parasitaemia goes up (i.e. recrudescence) the blood⁄
plasma ratio might decrease. The question is whether
blood concentrations or plasma concentrations should be
compared.
Our study conﬁrms the limitations of PCR genotyping
(Baird 2004) for clearly distinguishing different types of
recurrences. It contributes to clarify the overall picture of
parasite recurrences as it establishes that a recurrent
parasite is a new parasite strain rather than the same strain
causing the infection for which the patient was treated
(recrudescence). However, it does not allow classifying
these recurrences as resistant parasites, which can only be
done with the help of blood chloroquine concentrations,
the most relevant analysis for assisting in the interpretation
of results.
In conclusion, our study combining in vivo efﬁcacy data
and chloroquine measurements⁄molecular analysis sug-
gests that, despite the lack of previous recent information
on P. vivax resistance in this area, resistance of P. vivax to
chloroquine is emerging in Myanmar, near the border of
Thailand. Although chloroquine remains the ﬁrst-line drug
for P. vivax infections in this area, regular monitoring is
needed to detect further development of parasite resistance.
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